Drugs, hERG and sudden death

Cell Calcium

Volumn 35, Issue 6, 2004, Pages 543-547

  Brown, A M ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b ChanTest Inc   (United States)

Author keywords

hERG; QT; Screens; Sudden death; Throughput

Indexed keywords

ACETYLSALICYLIC ACID; ALMOKALANT; AMIODARONE; AMOXICILLIN; ANTIBIOTIC AGENT; ASTEMIZOLE; BEPRIDIL; CAPTOPRIL; CHLORPHENIRAMINE MALEATE; CISAPRIDE; DIPHENHYDRAMINE; DOFETILIDE; ERYTHROMYCIN; FEXOFENADINE; GREPAFLOXACIN; HALOPERIDOL; LORATADINE; NEW DRUG; PIMOZIDE; PROPRANOLOL; QUINIDINE; RISPERIDONE; SERTINDOLE; SOTALOL; TERFENADINE; TERODILINE; THIORIDAZINE; UNINDEXED DRUG; VERAPAMIL; ZIPRASIDONE;

ARTICLE; DRUG DETERMINATION; DRUG MECHANISM; DRUG QUALITY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; QT PROLONGATION; RISK BENEFIT ANALYSIS; STANDARD; SUDDEN DEATH; SYNCOPE; TORSADE DES POINTES;

EID: 2442562493     PISSN: 01434160     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ceca.2004.01.008     Document Type: Article

References (11)

1. R.L. Woosley, Y. Chen, J.P. Froiman, R.A. Gillis, Mechanism of the cardiotoxic actions of terfenadine, JAMA 269 (1993) 1532-1536.
2. Kr potassium channel, Cell 81 (1995) 299-307.
3. M.L. Roy, R. Dumaine, A.M. Brown, hERG, a primary human ventricular target of the nonsedating antihistamine terfenadine, Circulation 94 (1996) 817-823.
4. D. Rampe, M.L. Roy, A. Dennis, A.M. Brown, A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel hERG, FEBS Lett. 417 (1997) 28-32.
5. + channel by the gastrointestinal prokinetic agent cisapride, Am. J. Physiol. 273 (1997) H2534-H2538.
6. A.E. Lacerda, J. Kramer, K.-Z. Shen, D. Thomas, A.M. Brown, Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs, Eur. Heart J. Suppl. 3 (2001) K23-K30.
7. c interval prolongation: a review, Am. J. Cardiol. 72 (1993) 23B-25B.
8. W.S. Redfern, L. Carlsson, A.S. Davis, et al., Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development, Cardiovasc. Res. 58 (2003) 32-45.
9. Hanson L, Barnett International QT Prolongation Conference, 2003.
10. E. Ficker, A.T. Dennis, L. Wang, A.M. Brown, Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel hERG, Circ. Res. 92 (2003) e87-e100.
11. G.A. Gintant, J.T. Limberis, J.S. McDermott, C.D. Wegner, B.F. Cox, The Canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis, J. Cardiovasc. Pharmacol. 37 (2001) 607-618.